Figure 1 (Divalproex Fig1)
Divalproex Sodium
Product Images NDC 50090-2795
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-2795). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Divalproex Fig2)
Figure 3 (Divalproex Fig3)
This appears to be a graph showing the % Reduction in CPS (Central Processing Unit) rate in high dose and low dose, with the number of patients on the y-axis and the level of improvement on the x-axis.*
Figure 4 (Divalproex Fig4)
This is a figure displaying the mean 4-week migraine rates for two studies comparing the use of a placebo versus delayed-release tablets of divalproex sodium for migraine treatment. The mean dose of divalproex sodium delayed-release tablets for study 1 was 1,087 mg/day, while for study 2, the dose ranged from 500 to 1,000 mg/day.*
Chemical Structure (Divalproex Str)
Label Image (Lbl500902795)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
